Pages
Products
AAV9-tMCK-GFP

AAV9-tMCK-GFP

Cat.No. :  AAV00284Z

Titer: ≥1x10^12 GC/mL / ≥1x10^13 GC/mL Size: 30 ul/100 ul/500 ul/1 ml

Serotype:  AAV Serotype 9 Storage:  -80 ℃

Inquire for Price

AAV Particle Information

Quality Control

Cat. No. AAV00284Z
Description AAV serotype 9 particles contain GFP under a muscle cell specific promoter (tMCK).
Reporter GFP
Serotype AAV Serotype 9
Application

1. Determination of optimal MOI (multiplicity of infection), administration methods etc.

2. Detection of the infection efficiency of the AAV serotype against a specific cell type or tissue.

3. Using reporter genes to visualize the distribution and expression of AAV vectors in live animals, helping assess the biodistribution and persistence of gene delivery.

Titer Varies lot by lot, typically ≥1x10^12 GC/mL
Size Varies lot by lot, for example, 30 μL, 50 μL, 100 μL etc.
Storage Store at -80℃. Avoid multiple freeze/thaw cycles.
Shipping Frozen on dry ice
Creative Biogene ensures high-quality AAV particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between AAV particle lots.
Endotoxin Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in the production of AAV, especially for applications in animal studies and gene therapy. Effective endotoxin quality control is essential in the development and manufacturing of AAV particles. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced AAV particles to ensure regulatory compliance.
Purity AAV purity is critical for ensuring the safety and efficacy of AAV-based applications.AAV capsids are composed of three main protein components, known as viral proteins: VP1, VP2, and VP3. These proteins play a critical role in the structure and functionality of the AAV capsid. Monitoring the VP1, VP2, and VP3 content in AAV preparations is essential for quality control in AAV production. Our AAV particles are tested for showing three clear bands of VP1, VP2 VP3 by SDS-PAGE.
Sterility The AAV virus samples are inoculated into the cell culture medium for about 5 days to detect bacterial and fungal growth.
Transducibility Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of AAV to deliver genetic material into target cells or tissues, and assess gene expression and functional activities.
Empty vs. Full Capsids Based-on our proprietary AAV production and purification technology, Creative Biogene can always offer AAV particles with high ratio of full capsids. If required, we can also assess the ratio for a specifc lot of AAV particles by transmission electron microscopy (TEM) or other methods.
Quick Inquiry

Background

Publications

Q & A

Customer Reviews

Adeno-associated viruses (AAVs) are small, single-stranded DNA viruses with a genome of approximately 4.7 kb that belong to the family Parvoviridae and the genus Dependoparvovirus. Due to their lack of pathogenicity and ability to deliver nearly any DNA sequence to target tissues in mammalian species, AAVs have become the gene therapy vector of choice for both basic research and clinical applications. Since the approval of alipogene tiparvovec (Glybera) in Europe in 2012 for the treatment of lipoprotein lipase deficiency, voretigene neparvovec-rzyl (Luxturna) in the United States in 2017 for the treatment of RPE365−/− Leber congenital amaurosis and retinitis pigmentosa, and onasemnogene abeparvovec (Zolgensma) in the United States in 2019 for the treatment of spinal muscular atrophy, the number of clinical trials for AAV-based therapies has increased dramatically, with more than 200 clinical trials registered to date. AAV species are designated by the serotype of their capsid protein. Among the commonly used serotypes, AAV serotype 9 (AAV9) is frequently used for skeletal, cardiac, and neurological applications, including the AAV9 biopharmaceutical onasemnogene abeparvovec. For the heart, AAV9 has become the dominant serotype in preclinical studies. AAV, including serotype 9, has a pronounced tropism for the liver, and AAV9 biologics have demonstrated significant extrahepatic delivery when delivered via coronary artery infusion.
Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Customizable Solutions

Creative Biogene's team of experts offered insightful guidance on vector design and optimization, enabling us to achieve optimal results. This level of personalized service and expertise is rare and adds immense value to their already exceptional product offerings.

French

08/19/2024

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction